- Home
- CHH vs LNTH Comparison
CHH vs LNTH Comparison
Compare CHH & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHH
- LNTH
- Stock Information
- Founded
- CHH 1939
- LNTH 1956
- Country
- CHH United States
- LNTH United States
- Employees
- CHH N/A
- LNTH N/A
- Industry
- CHH Hotels/Resorts
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CHH Consumer Discretionary
- LNTH Health Care
- Exchange
- CHH Nasdaq
- LNTH Nasdaq
- Market Cap
- CHH 5.7B
- LNTH 5.7B
- IPO Year
- CHH 1997
- LNTH 2015
- Fundamental
- Price
- CHH $134.36
- LNTH $81.47
- Analyst Decision
- CHH Hold
- LNTH Strong Buy
- Analyst Count
- CHH 14
- LNTH 5
- Target Price
- CHH $134.43
- LNTH $131.20
- AVG Volume (30 Days)
- CHH 447.3K
- LNTH 932.7K
- Earning Date
- CHH 08-06-2025
- LNTH 07-30-2025
- Dividend Yield
- CHH 0.86%
- LNTH N/A
- EPS Growth
- CHH 40.19
- LNTH N/A
- EPS
- CHH 6.57
- LNTH 3.53
- Revenue
- CHH $797,663,000.00
- LNTH $1,536,699,000.00
- Revenue This Year
- CHH $103.49
- LNTH $4.63
- Revenue Next Year
- CHH $3.35
- LNTH $9.35
- P/E Ratio
- CHH $20.46
- LNTH $23.03
- Revenue Growth
- CHH N/A
- LNTH 12.53
- 52 Week Low
- CHH $116.20
- LNTH $73.11
- 52 Week High
- CHH $157.86
- LNTH $126.89
- Technical
- Relative Strength Index (RSI)
- CHH 65.36
- LNTH 50.75
- Support Level
- CHH $130.42
- LNTH $78.74
- Resistance Level
- CHH $135.89
- LNTH $85.31
- Average True Range (ATR)
- CHH 2.63
- LNTH 2.28
- MACD
- CHH 0.84
- LNTH 0.51
- Stochastic Oscillator
- CHH 89.62
- LNTH 45.38
About CHH Choice Hotels International Inc.
As of Dec. 31, 2024, Choice Hotels operated 654,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (26% of the company's total domestic rooms), while Ascend and Cambria (10% of total domestic rooms) are newer lifestyle and select-service brands. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2024.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.